[
  {
    "ts": null,
    "headline": "Should You Add CVS Health Stock to Your Portfolio Before Q3 Earnings?",
    "summary": "CVS Health prepares Q3 results, with pharmacy performance and Aetna's progress in focus for investors.",
    "url": "https://finnhub.io/api/news?id=dc36dcde122b3a3fcb5f0fd8bdfb7060fa7fd2db5ca64069a124d30448c970fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760624340,
      "headline": "Should You Add CVS Health Stock to Your Portfolio Before Q3 Earnings?",
      "id": 137121805,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "CVS Health prepares Q3 results, with pharmacy performance and Aetna's progress in focus for investors.",
      "url": "https://finnhub.io/api/news?id=dc36dcde122b3a3fcb5f0fd8bdfb7060fa7fd2db5ca64069a124d30448c970fd"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street's Insights Into Key Metrics Ahead of Elevance Health (ELV) Q3 Earnings",
    "summary": "Besides Wall Street's top-and-bottom-line estimates for Elevance Health (ELV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.",
    "url": "https://finnhub.io/api/news?id=982247e3df8cd46f40b2728a77fe2de1c3ed1a3d607425f2350763a5906a1144",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760620506,
      "headline": "Wall Street's Insights Into Key Metrics Ahead of Elevance Health (ELV) Q3 Earnings",
      "id": 137122118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "Besides Wall Street's top-and-bottom-line estimates for Elevance Health (ELV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.",
      "url": "https://finnhub.io/api/news?id=982247e3df8cd46f40b2728a77fe2de1c3ed1a3d607425f2350763a5906a1144"
    }
  },
  {
    "ts": null,
    "headline": "Analyzing Elevance Health After ACA Subsidy Uncertainty Drives Big Swings in 2025",
    "summary": "If you have been watching Elevance Health, you have probably noticed some dramatic moves lately. After a strong bounce of nearly 14% over the last month, the stock recently slipped by 3.5% in just a week. It has not been an easy ride this year, off about 4.5% year to date, and the one-year return is down a steep 28.4%. Despite the rough stretch, Elevance still boasts a solid 26% return if you zoom out to five years. So, what is behind the rollercoaster, and how should investors think about...",
    "url": "https://finnhub.io/api/news?id=48f62a910874d6c94d6a45fa63d70d52e061bbfba4b1c472567709515b893975",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760591228,
      "headline": "Analyzing Elevance Health After ACA Subsidy Uncertainty Drives Big Swings in 2025",
      "id": 137102143,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "If you have been watching Elevance Health, you have probably noticed some dramatic moves lately. After a strong bounce of nearly 14% over the last month, the stock recently slipped by 3.5% in just a week. It has not been an easy ride this year, off about 4.5% year to date, and the one-year return is down a steep 28.4%. Despite the rough stretch, Elevance still boasts a solid 26% return if you zoom out to five years. So, what is behind the rollercoaster, and how should investors think about...",
      "url": "https://finnhub.io/api/news?id=48f62a910874d6c94d6a45fa63d70d52e061bbfba4b1c472567709515b893975"
    }
  },
  {
    "ts": null,
    "headline": "Humana Loses Court Battle Over Medicare Advantage Ratings, Billions In Payments At Risk",
    "summary": "Humana Inc. (NYSE:HUM) lost a legal battle challenging cuts to its Medicare Advantage bonus payments, raising concerns over billions in potential revenue. Per a media report on Tuesday, a Texas judge ruled in favor of the federal government and upheld the downgrade of Humana's star ratings—ratings that are directly tied to the payments private insurers receive under Medicare Advantage. The ruling marks a setback for Humana, which had argued that the government's decision to lower some of its sta",
    "url": "https://finnhub.io/api/news?id=cb29298ff7de923cd649d356b3e5e3011981ad7eec2d85d095ee3ebf6ce44242",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760574666,
      "headline": "Humana Loses Court Battle Over Medicare Advantage Ratings, Billions In Payments At Risk",
      "id": 137100559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "Humana Inc. (NYSE:HUM) lost a legal battle challenging cuts to its Medicare Advantage bonus payments, raising concerns over billions in potential revenue. Per a media report on Tuesday, a Texas judge ruled in favor of the federal government and upheld the downgrade of Humana's star ratings—ratings that are directly tied to the payments private insurers receive under Medicare Advantage. The ruling marks a setback for Humana, which had argued that the government's decision to lower some of its sta",
      "url": "https://finnhub.io/api/news?id=cb29298ff7de923cd649d356b3e5e3011981ad7eec2d85d095ee3ebf6ce44242"
    }
  }
]